Neurotech Pulse Issue #41 roundup

Neurotech Pulse Issue #41 pulls together a set of recent transactions, filings and study launches that show where neurotechnology companies are spending time and money in 2026. The items range from Datasea’s U.S. Food and Drug Administration registration step for an acoustic biofeedback system to Ottobock’s planned acquisition of Spanish neuro-orthotics company Fesia, Neurolief’s new Department of Veterans Affairs contract, and SoundHealth’s $12.25 million Series A financing. The issue also points to a second lane in the market: programs built around measurement and validation. ARPA-H award pages show chronic-pain projects using multimodal wearables to track biomarkers and vital signs, while Adaptyx Biosciences and Attune Neurosciences said on August 11 they launched an ARPA-H-backed study tied to Attune’s focused-ultrasound chronic-pain trial. ### Why did Datasea’s FDA step get attention if it was not a clearance? Datasea said on August 11 that its NeuroVibe acoustic BCI biofeedback system had been registered and device-listed with the FDA as a Class II 510(k)-exempt biofeedback medical device. (prnewswire.com) The company described the move as part of its acoustic medical strategy and a step toward commercial deployment. (arpa-h.gov) A June 12 Datasea release had framed the process more narrowly, saying the company was advancing compliance work and related procedures for FDA establishment registration and device listing for one of its acoustic brain-computer interface products. That matters because registration and listing are not the same as FDA clearance or approval for a novel device claim. (prnewswire.com) ### What exactly is Ottobock buying in neuro-orthotics? Ottobock said on July 7 it agreed to acquire Fesia Technology, a Donostia/San Sebastián, Spain-based company that develops functional electrical stimulation systems for patients with neurological diseases or injuries. Ottobock said the deal would expand its neuro-orthotics portfolio in functional electrical stimulation, or FES. (prnewswire.com) Fesia employs around 20 people, according to Ottobock’s announcement, and the purchase price was not disclosed. Ottobock said closing is expected in approximately six months, giving the deal a defined timetable rather than an open-ended strategic statement. ### How far does Neurolief’s VA contract move commercialization? Neurolief said on August 11 that U.S. (eqs-news.com) Department of Veterans Affairs sites had begun prescribing Proliv Rx for major depressive disorder and Relivion MG for migraine under a new VA contract. The company said multiple VA medical centers were prescribing the therapies within the Veterans Health Administration, which it described as serving nine million enrolled veterans annually. Proliv Rx received FDA approval in December 2025, Neurolief said, as an at-home brain neuromodulation therapy for adults with major depressive disorder who had not achieved adequate improvement with antidepressant medication. The VA contract therefore points less to early research and more to channel access inside a large U.S. care system. (prnewswire.com) ### What does the SoundHealth raise say about investor appetite? SoundHealth said it closed an oversubscribed Series A financing led by Shangbay Capital, bringing total funding to date to $12.25 million. The company said the money would support growth of its FDA-cleared, personalized therapeutics for breathing and sleep disorders. (prnewswire.com) The financing sits adjacent to neurotech rather than at its center, but it fits the same pattern seen across the roundup: investors are still backing non-invasive platforms that already have a regulatory foothold and a defined commercial use case. That reading is an inference from the company’s financing terms and product positioning. (businesswire.com) ### Why are ARPA-H pain-biomarker studies part of the same story? ARPA-H award pages show two women’s-health pain-measurement projects that rely on wearables and machine learning. One Caltech-led project carries funding of up to $3.4 million and aims to monitor sweat biomarkers and vital signs to predict pain levels in real time in women with menstrual migraines. A separate Tufts-led project, also funded up to $3.4 million, is building a smart bandage platform to quantify pain using biochemical and biophysical markers. (businesswire.com) Adaptyx Biosciences said on August 11 that it launched a 24-month ARPA-H-backed study with Attune Neurosciences to identify an objective molecular signature of chronic pain. Patients in Attune’s Phase II trial of investigational focused-ultrasound treatment will wear Adaptyx sensors around treatment sessions, while Attune describes its own platform as a wearable, adaptive ultrasound deep-brain therapy system. (arpa-h.gov) Ottobock’s Fesia acquisition is expected to close in about six months, according to the company. ARPA-H-backed pain studies at Caltech, Tufts, Adaptyx and Attune are already underway, and Datasea, Neurolief and SoundHealth have each tied their latest announcements to commercialization or deployment steps rather than basic research alone. (eqs-news.com) (finance.yahoo.com)